When did moboxetinib begin to be sold in China?

Mobocertinib is an investigational first-in-class oral tyrosine kinase inhibitor (TKI) specifically designed to selectively target epidermal growth factor receptor (EGFR) exon 20 insertion mutations. In January 2020, the China Center for Drug Evaluation (CDE) designated mobosetinib as a breakthrough therapy for the treatment of patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR exon 20 insertion mutations who have received at least one previous systemic chemotherapy.

As of January 2024, mobosetinibthe original drug has been on the market for sale in China for some time, and domestic hospitals and other places may have this drug for sale. No oral EGFR-targeted therapies are approved for EGFR exon 20 insertion (EGFRex20ins) mutation-driven non-small cell lung cancer. Mobosetinib is a new type of small molecule EGFR inhibitor, specifically designed for EGFRex20ins mutants.

Mobosetinib's original drug has not yet been included in the medical insurance and is priced at around 40,000 yuan per box of 40mg*112 pills, which is very expensive. The Hong Kong version of the original drug specification40mg*30 pills per box is priced at more than 7,000 yuan (the price may fluctuate due to exchange rates). Generic drugs of Mobotinib have also been put on the market for sale overseas. Its pharmaceutical ingredients are basically the same as those of the original drugs at home and abroad. For example, the production specifications of Laos Pharmaceutical Factory 40mg*120 pills per box may be more than 4,000 yuan (the price may fluctuate due to the exchange rate), and the price is relatively cheap.